Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy.
Interim Analysis of a Two-Institution, Prospective Clinical Trial of 4DCT-Ventilation-based Functional Avoidance Radiation Therapy.
复制标题
DOI：
10.1016/j.ijrobp.2018.07.186
复制
发表时间：
2018-11-15
期刊：
影响因子：
--
通讯作者：
Grills I
中科院分区：
文献类型：
--
作者：
Vinogradskiy Y;Rusthoven CG;Schubert L;Jones B;Faught A;Castillo R;Castillo E;Gaspar LE;Kwak J;Waxweiler T;Dougherty M;Gao D;Stevens C;Miften M;Kavanagh B;Guerrero T;Grills I
Functional imaging has been proposed that uses 4DCT images to calculate 4DCT-based lung ventilation (4DCT-ventilation). We have started a 2-institution, phase 2 prospective trial evaluating the feasibility, safety, and preliminary efficacy of 4DCT-ventilation functional avoidance. The trial hypothesis is that the rate of grade ≥2 radiation pneumonitis could be reduced to 12% with functional avoidance, compared with a 25% rate of pneumonitis with a historical control. The trial employed a Simon 2-stage design with a planned futility analysis after 17 evaluable patients. The purpose of this work is to present the trial design and implementation, dosimetric data, and clinical results for the planned futility analysis. Eligible patients were patients with lung cancer who were prescribed doses of 45 to 75 Gy. For each patient, the 4DCT data were used to generate a 4DCT-ventilation image using the Hounsfield unit technique along with a compressible flow-based image registration algorithm. Two intensity modulated radiation therapy treatment plans were generated: (1) a standard lung plan and (2) a functional avoidance treatment plan that aimed to reduce dose to functional lung while meeting target and normal tissue constraints. Patients were treated with the functional avoidance plan and evaluated for thoracic toxicity (presented as rate and 95% confidence intervals [CI]) with a 1-year follow-up. The V20 to functional lung was 21.6% ± 9.5% (mean ± standard deviation) with functional avoidance, representing a decrease of 3.2% (P < .01) relative to standard, nonfunctional treatment plans. The rates of grade ≥2 and grade ≥3 radiation pneumonitis were 17.6% (95% CI, 3.8%−43.4%) and 5.9% (95% CI, 0.1%−28.7%), respectively. Dosimetrically, functional avoidance achieved reduction in doses to functional lung while meeting target and organ at risk constraints. On the basis of Simon’s 2-stage design and the 17.6% grade ≥2 pneumonitis rate, the trial met its futility criteria and has continued accrual. Functional avoidance has been proposed as a means of using functional imaging to reduce the dose to functional regions of the lung in order to reduce thoracic toxicity. We have started a 2-institution, early-phase clinical trial to use a novel lung functional imaging modality (termed 4-dimensional computed tomography-ventilation) for functional avoidance radiation therapy. The purpose of this work is to present the trial design and implementation, dosimetric results, and an interim clinical toxicity analysis.
Functional imaging has been proposed that uses 4DCT images to calculate 4DCT-based lung ventilation (4DCT-ventilation). We have started a 2-institution, phase 2 prospective trial evaluating the feasibility, safety, and preliminary efficacy of 4DCT-ventilation functional avoidance. The trial hypothesis is that the rate of grade ≥2 radiation pneumonitis could be reduced to 12% with functional avoidance, compared with a 25% rate of pneumonitis with a historical control. The trial employed a Simon 2-stage design with a planned futility analysis after 17 evaluable patients. The purpose of this work is to present the trial design and implementation, dosimetric data, and clinical results for the planned futility analysis. Eligible patients were patients with lung cancer who were prescribed doses of 45 to 75 Gy. For each patient, the 4DCT data were used to generate a 4DCT-ventilation image using the Hounsfield unit technique along with a compressible flow-based image registration algorithm. Two intensity modulated radiation therapy treatment plans were generated: (1) a standard lung plan and (2) a functional avoidance treatment plan that aimed to reduce dose to functional lung while meeting target and normal tissue constraints. Patients were treated with the functional avoidance plan and evaluated for thoracic toxicity (presented as rate and 95% confidence intervals [CI]) with a 1-year follow-up. The V20 to functional lung was 21.6% ± 9.5% (mean ± standard deviation) with functional avoidance, representing a decrease of 3.2% (P < .01) relative to standard, nonfunctional treatment plans. The rates of grade ≥2 and grade ≥3 radiation pneumonitis were 17.6% (95% CI, 3.8%−43.4%) and 5.9% (95% CI, 0.1%−28.7%), respectively. Dosimetrically, functional avoidance achieved reduction in doses to functional lung while meeting target and organ at risk constraints. On the basis of Simon’s 2-stage design and the 17.6% grade ≥2 pneumonitis rate, the trial met its futility criteria and has continued accrual. Functional avoidance has been proposed as a means of using functional imaging to reduce the dose to functional regions of the lung in order to reduce thoracic toxicity. We have started a 2-institution, early-phase clinical trial to use a novel lung functional imaging modality (termed 4-dimensional computed tomography—ventilation) for functional avoidance radiation therapy. The purpose of this work is to present the trial design and implementation, dosimetric results, and an interim clinical toxicity analysis.
登录
查看更多内容
影响因子：
51.1
作者：
Bradley, Jeffrey D.;Paulus, Rebecca;Komaki, Ritsuko;Masters, Gregory;Blumenschein, George;Schild, Steven;Bogart, Jeffrey;Hu, Chen;Forster, Kenneth;Magliocco, Anthony;Kavadi, Vivek;Garces, Yolanda I.;Narayan, Samir;Iyengar, Puneeth;Robinson, Cliff;Wynn, Raymond B.;Koprowski, Christopher;Meng, Joanne;Beitler, Jonathan;Gaur, Rakesh;Curran, Walter, Jr.;Choy, Hak
通讯作者：
Choy, Hak
DOI：
10.1016/j.ijrobp.2009.06.091
发表时间：
2010-03-01
影响因子：
7
作者：
Marks, Lawrence B.;Bentzen, Soren M.;Deasy, Joseph O.;Kong, Feng-Ming (Spring);Bradley, Jeffrey D.;Vogelius, Ivan S.;El Naqa, Issam;Hubbs, Jessica L.;Lebesque, Joos V.;Timmerman, Robert D.;Martel, Mary K.;Jackson, Andrew
通讯作者：
Jackson, Andrew
影响因子：
4.8
作者：
Mathew, Lindsay;Wheatley, Andrew;Parraga, Grace
通讯作者：
Parraga, Grace
DOI：
10.1016/s1470-2045(17)30318-2
发表时间：
2017-08
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Faivre-Finn C;Snee M;Ashcroft L;Appel W;Barlesi F;Bhatnagar A;Bezjak A;Cardenal F;Fournel P;Harden S;Le Pechoux C;McMenemin R;Mohammed N;O'Brien M;Pantarotto J;Surmont V;Van Meerbeeck JP;Woll PJ;Lorigan P;Blackhall F;CONVERT Study Team
通讯作者：
CONVERT Study Team
影响因子：
5.7
作者：
Christian, JA;Partridge, M;Brada, M
通讯作者：
Brada, M